NVO
stock·CLOSEDNYSE/NASDAQNovo Nordisk A/S — Danish pharma leader in diabetes and obesity drugs (Ozempic, Wegovy).
loading charts…
News
13- NVO▲Novo Nordisk expects to launch Wegovy pill in Germany in September2d
- NVO▼Novo Nordisk Q2 operating profit negatively affected by US 340B rebate provision reversal×23d
- NVO▲Novo Nordisk raises outlook, driven by improved GLP-1 sales expectations×23d
- NVO▼Novo Nordisk to take Q3 non-cash impairment after ZEUS outcome7d
| Exchange | Symbol | Mark | Index | Basis | FundingEach venue's rate is converted to an hourly equivalent. Annualized funding = hourly rate × 24 × 365 (not compounded). Multi-venue values are weighted by 24h volume. | Volume 24h | Vol % | OI (USD) | Live |
|---|---|---|---|---|---|---|---|---|---|
 | NVO_USDT | 47.00 | 47.07 | -14.9 bps | --:--:--+0.0100%(+10.95% ann) | $337.87K | 59.1% | $230.3K | 72d |
 | NVOUSDT | 47.10 | 47.10 | +0.0 bps | --:--:--+0.0000%(+0.00% ann) | $113.33K | 19.8% | $27.44K | 1d |
 | NVOSTOCK_USDT | 47.07 | 47.09 | -4.2 bps | --:--:--+0.0000%(+0.00% ann) | $105.4K | 18.4% | $276.66K | 68d |
 ondo | NVO | 48.09 | 47.08 | +214.8 bps | — | $7.62K | 1.3% | — | ≥365d |
 ondo | NVOon | 47.08 | — | — | — | $7.62K | 1.3% | — | 181d |
 | NVOUSDT | 47.07 | 47.12 | -8.9 bps | --:--:--+0.0000%(+0.00% ann) | — | — | $496.32K | 68d |
 backed | XsfAzP…87S57n | 45.95 | 47.08 | -239.3 bps | — | — | — | — | 181d |